scholarly journals Hypercoagulation Screening as Marker of Occult Cancer in a Population of Healthy Blood Donors: The Hypercan Prospective Study

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 2604-2604
Author(s):  
Anna Falanga ◽  
Marina Marchetti ◽  
Sara Gamba ◽  
Laura Russo ◽  
Carmen Julia Tartari ◽  
...  
Keyword(s):  
General Population ◽  
Cancer Diagnosis ◽  
Preliminary Analysis ◽  
Blood Donors ◽  
Response To Therapy ◽  
Healthy Population ◽  
Tumor Type ◽  
Early Cancer Diagnosis ◽  
Age Range

Abstract INTRODUCTION and AIM: The HYPERCAN study is an ongoing prospective Italian multicenter trial, designed to test whether the persistence of a laboratory hypercoagulation abnormalities may predict early cancer diagnosis in healthy subjects (Project A), or prognosis and response to therapy in patients with cancer (Project B). The aim of this abstract is to present a preliminary analysis of data collected for project A. MATERIAL AND METHODS: A large healthy population of Italian blood donors from Bergamo and Milan areas (North Italy) is prospectively enrolled after informed written consent and followed-up for 5 years for the occurrence of cancer. As established by a monitoring schedule, blood donors are periodically screened for a series of serological, biochemical and clinical parameters, and tested for viral infections. We plan to enroll 10,000 donors of both gender, age range 35-65, in 5 years. Blood samples from each study subject are collected at enrollment and after 8-10 months, and processed to obtain plasma, buffy coat, and serum subsamples, which are stored in a dedicated biobank until testing for hypercoagulation biomarkers. Demographic and clinical data are collected, including age, gender, body mass index (BMI), current medications, relevant comorbidities, routine hematological and biochemical workup. In addition, subjects are asked to fill in a questionnaire on lifestyle, smoke and dietary habits. An identification of all malignant tumors, according to the categories 140-208 (International Classification of Diseases) is carried out every 6 months. RESULTS: Between April 2012 and June 2016, 6,607 blood donors (70% males; median age 48 years) have been recruited. Routine biochemical and hematological workups are into the normal range values in more than 90% of subjects. The analysis of questionnaires reveals that 57% of the donors were not smokers, 15% regular smokers, 28% ex-smokers; 49% of them were moderate/low alcohol consumer (≥ 2 drink/die). The crude incidence of all malignant cancers in the Bergamo/Milan area is 552 cases/100,000 persons/year in males and 382 cases/100,000 person/year in females. According to the Cancer Registry, 57 cancer cases (38 males and 19 females) are to be expected in the general population in the age range 35-65 years, after a median follow-up of 2.5 years. In our population, at June 2016, after a median follow-up of 2.5 years, we recorded a total of 46 cancer cases (35 M / 11 F). Five cases were excluded because diagnosis occurred within 6 months from enrollment (incident cancer cases); the remaining 41 cases included in the analysis were diagnosed with cancer 6-28 months from enrollment (median time to diagnosis = 24.8 months). Median age at diagnosis of cancer was 53 years. The most frequent tumor type in male donors was prostate cancer (25.8%), followed by colo-rectal (19.3%) and thyroid (12.9%) cancers. In female donors, breast cancer was the most frequent (40%). Currently, the enrollment of healthy donors and follow-up is ongoing, as well as the identification of new cancer cases. Next, according to the original plan, samples from 3 matched cancer-free donors for each cancer-case donor (cancer: non-cancer = 1:3 ratio) will be analyzed in parallel for hypercoagulation markers. CONCLUSIONS: This preliminary analysis reveals that the distribution of tumor types in our population reflects the same as reported for the general population of the same geographic area. Second, in our population of healthy blood donors, the incidence of cancer diagnosis is lower than that predicted from epidemiological data. This message supports the concept that a healthy lifestyle can be effective to prevent cancer. Project funded by AIRC "5xMILLE" n. 12237 grant from the "Italian Association for Cancer Research (AIRC)". Disclosures Falanga: Pfizer: Speakers Bureau; Aspen: Speakers Bureau; Janssen: Speakers Bureau.

scholarly journals High-level Exposure of Uric Acid in Asymptomatic Hyperuricemia Could Be An Isolated Risk Factors of Cardio-Cerebrovascular Diseases: A Prospective Cohort Study

2021 ◽  
Author(s):  
Zhiyuan Cheng ◽  
Tongzhang Zheng ◽  
Desheng Zhang ◽  
Jingli Yang ◽  
Xiaobin Hu ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Uric Acid ◽  
Cox Regression ◽  
Cerebrovascular Diseases ◽  
Healthy Population ◽  
Incidence Risk ◽  
High Level ◽  
Age Range ◽  
Fourth Quartile

Abstract Background: Whether the asymptomatic hyperuricemia (AH) raises the risk of cardiovascular disease with or without hyperuricemia-related comorbidities still remains contentious. Our study was aimed to quantitatively access the incidence risk of coronary heart disease (CHD) and stroke associated with AH.Methods: Multivariate-adjusted Cox regression models were applied to evaluate the risk of cardiovascular disease (CVD). Serum uric acid beyond normouricemia was quarterly stratified based on the distribution of healthy population without CVD onset.Results: 1,062 CVD first attack cases were collected among the 48,001 cohort participants (age range: 18-92, mean age: 47.2±13.9 years-old) with a mean follow-up duration of 5.78±0.83 years. 14,464 baseline population with comorbidities were excluded to further study the association between AH and CVD incidence. The AH showed overall non-association with CVD incident. However, significantly increased adjusted hazard ratio (HR) of CVD with 95% confidence interval (CI) were observed when the fourth quartile compared with normouricemia stratum in the total cohort population (CHD: 1.70, 1.34-2.16; stroke: 1.55, 1.13-2.13), male (CHD: 1.94, 1.47-2.56), female (CHD: 1.71, 1.03-2.35; stroke: 2.02, 1.14-3.58) and aged over 50 years-old population. Meanwhile, the age-standardized incidence rate of CVD in the fourth quartile was 2 to 3 time higher than the normouricemia population. Consistent results were also observed in the AH population in absence of comorbidities (CHD: 2.40, 1.39-4.14; stroke: 1.85, 1.12-3.59).Conclusion: Asymptomatic hyperuricemia patients exposed to higher level of uric acid (male>487 mmol/L, female>422 mmol/L) could significantly increase the incidence risk of CHD and stroke, with or without hyperuricemia-related comorbidities.

scholarly journals A population-based study of cardiovascular disease mortality risk in US cancer patients

2019 ◽  
Vol 40 (48) ◽  
pp. 3889-3897 ◽  
Author(s):  
Kathleen M Sturgeon ◽  
Lei Deng ◽  
Shirley M Bluethmann ◽  
Shouhao Zhou ◽  
Daniel M Trifiletti ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Heart Disease ◽  
General Population ◽  
Cancer Diagnosis ◽  
Mortality Risk ◽  
First Year ◽  
Cardiovascular Disease Mortality ◽  
Disease Mortality ◽  
Cvd Mortality

Abstract Aims This observational study characterized cardiovascular disease (CVD) mortality risk for multiple cancer sites, with respect to the following: (i) continuous calendar year, (ii) age at diagnosis, and (iii) follow-up time after diagnosis. Methods and results The Surveillance, Epidemiology, and End Results program was used to compare the US general population to 3 234 256 US cancer survivors (1973–2012). Standardized mortality ratios (SMRs) were calculated using coded cause of death from CVDs (heart disease, hypertension, cerebrovascular disease, atherosclerosis, and aortic aneurysm/dissection). Analyses were adjusted by age, race, and sex. Among 28 cancer types, 1 228 328 patients (38.0%) died from cancer and 365 689 patients (11.3%) died from CVDs. Among CVDs, 76.3% of deaths were due to heart disease. In eight cancer sites, CVD mortality risk surpassed index-cancer mortality risk in at least one calendar year. Cardiovascular disease mortality risk was highest in survivors diagnosed at <35 years of age. Further, CVD mortality risk is highest (SMR 3.93, 95% confidence interval 3.89–3.97) within the first year after cancer diagnosis, and CVD mortality risk remains elevated throughout follow-up compared to the general population. Conclusion The majority of deaths from CVD occur in patients diagnosed with breast, prostate, or bladder cancer. We observed that from the point of cancer diagnosis forward into survivorship cancer patients (all sites) are at elevated risk of dying from CVDs compared to the general US population. In endometrial cancer, the first year after diagnosis poses a very high risk of dying from CVDs, supporting early involvement of cardiologists in such patients.

Incidence of bone metastases among children with cancer in Denmark.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1579-1579 ◽  
Author(s):  
Rohini Khorana Hernandez ◽  
Vera Ehrenstein ◽  
Merete Lund Mægbæk ◽  
Alexander Liede ◽  
Henrik Toft Sørensen
Keyword(s):  
Bone Metastases ◽  
Cancer Diagnosis ◽  
Case Reports ◽  
Rare Event ◽  
Case Series ◽  
Incidence Rates ◽  
Tumor Type ◽  
Children With Cancer ◽  
Registration System

1579 Background: There are no published population-based studies on the incidence of bone metastases (BM) among children with cancer. The current literature is limited to small case series or case reports. Methods: We used the Danish Cancer Registry (DCR) to identify children <18 years old diagnosed with cancer between 1/1/1994 and 12/31/2009. Patients were followed from cancer diagnosis to BM, emigration, death, or end of study (1/1/2011). DCR data were linked to (1) Danish Civil Registration System to obtain information on death and emigration, and (2) Danish National Registry of Patients to identify ICD-10 codes for BM. We estimated incidence rates (IRs) of BM and mortality rates overall and stratified by gender, calendar year, age, and primary tumor type. Results: During the study period, 2,652 children were identified with a first-time diagnosis of cancer, of whom 35 (1.3%) developed BM (mean follow-up of 7.0 years). The IR of BM was 1.9 per 1,000 person-years (95% CI: 1.4 – 2.6); the highest rates occurred in children aged 12 – 17 years and among those with osteosarcoma (Table). Twenty-one (60%) children with BM died during follow-up, yielding a mortality rate of 192 per 1,000 person-years (95% CI: 125 – 295). The median time from cancer diagnosis to BM was 221 days and from BM to death was 283 days. Conclusions: This study represents the first comprehensive examination of BM in children and reveals that BM is a rare event, with median survival of less than one year from diagnosis. [Table: see text]

Survivorship among the Aged Blind

1965 ◽  
Vol 59 (10) ◽  
pp. 333-338
Author(s):  
Eugene Rogot
Keyword(s):  
General Population ◽  
Life Expectancy ◽  
Causes Of Death ◽  
Excess Mortality ◽  
Follow Up Study ◽  
One Year ◽  
Blind Persons ◽  
Age Range

A follow-up study of 11,732 persons first registered as legally blind in Massachusetts during the twenty-year period, 1940-1959, was conducted in order to determine survivorship patterns and causes of death among the blind. This paper reports findings for 5,976 blind persons who were sixty-five years of age or older at the time of registration. Life-expectancy values calculated for single years of age from sixty-five to ninety showed that blind males had lower values than the general population over most of this age range; differences in life-expectancy were roughly two years for ages sixty-five to seventy-two, about one year for ages seventy-three to seventy-nine, and essentially no difference for ages eighty to ninety. The pattern for females was very similar to that for males. The largest differences according to major causes of blindness were for diabetes with blind males age sixty-five and over having an observed life-expectancy almost four years less than expected, and blind females age sixty-five and over having a life-expectancy 4.8 years less than expected. For blind males as well as for blind females age sixty-five and over, excess mortality due to diabetes was particularly noted.

The epidemiology of herpes zoster in patients with invasive cancer

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 9562-9562 ◽  
Author(s):  
L. A. Habel ◽  
G. T. Ray ◽  
M. Horberg ◽  
B. Yawn ◽  
A. Castillo ◽  
...  
Keyword(s):  
Herpes Zoster ◽  
General Population ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Hematologic Malignancy ◽  
Incidence Rates ◽  
Cancer Type ◽  
Adult Health ◽  
Kaiser Permanente

9562 Background: Given the limited available data, the aim of this study was to estimate the incidence of Herpes Zoster (HZ) in cancer patients. Methods: In this retrospective cohort study, we used the Kaiser Permanente Northern California cancer registry to identify adult health plan members diagnosed with an invasive hematologic malignancy (HM) or solid tumor malignancy (STM) during 2001–2005. Potential episodes of HZ were ascertained from time of cancer diagnosis through 2006 from electronic databases using inpatient and outpatient diagnoses, laboratory tests, and prescriptions for antivirals. HZ diagnoses were confirmed by abstraction and clinical review of information from patients' inpatient and outpatient medical records. Incidence rates were calculated as the number of new occurrences of HZ per person-time of follow-up. Age-standardized incidence ratios (SIRs) were computed to compare HZ rates in cancer patients to reported rates in the general population (Yawn et al, 2007). Results: Among the 4,728 STM patients (mean age 66 years, range 18–102), the rate of HZ was 12/1000 person years (py) of follow-up (total 9170 py). Among the 1504 HM patients (mean age 67 years, range 18–97), the rate of HZ was 33/1000 py (total 2355 py). The SIRs and 95% confidence intervals for STM and HM were 1.7 (1.4–2.1) and 4.5 (3.5–5.6), respectively. Among patients with HM, incidence rates were highest in the first year after cancer diagnosis (40/1000 py); rates did not appear to vary markedly over time among patients with STM. For either cancer type, HZ rates were similar for males and females and did not increase consistently with increasing age. Conclusions: Compared to the general population, the incidence of HZ was nearly 2 times higher in patients with STM and over 4 times higher in patients with HM. HZ rates did not differ markedly by age or gender. [Table: see text]

Dynamics ofLegionellaantibody levels during 1 year in a healthy population

2008 ◽  
Vol 137 (7) ◽  
pp. 1013-1018 ◽  
Author(s):  
M. RUDBECK ◽  
K. MØLBAK ◽  
S. A. ULDUM
Keyword(s):  
Blood Donors ◽  
Antibody Test ◽  
Severe Illness ◽  
Healthy Population ◽  
Antibody Titres ◽  
History Of ◽  
Absence From Work ◽  
Immunofluorescence Antibody Test ◽  
Immunofluorescence Antibody

SUMMARYA total of 522 Danish blood donors were followed during 2004–2005 to describe the seroepidemiology ofLegionellainfections in healthy individuals from a general population. Antibodies toLegionellaspp. were measured by indirect immunofluorescence antibody test. The prevalence ofLegionellaantibodies (titre ⩾1:128) was 26·8% and remained fairly constant during the year of follow-up. However, 6·9% of the blood donors developed a fourfold or greater rise in antibody titres. A history of visits to Danish summer cottages was associated with bothLegionellaseropositivity (OR 1·53, 95% CI 1·02–2·30) and seroconversion (OR 2·66, 95% CI 1·21–5·83). There were no consistent associations between either levels of antibody titres or seroconversion and self-reported health symptoms, absence from work due to illness, or to any risk factors. We conclude that community-acquiredLegionellainfections are frequent; however, they rarely result in severe illness.

Renal impairment after chemotherapy in lung (LC), colorectal (CRC), and breast cancer (BC) patients (pts) from the Henry Ford Health System (HFHS) tumor registry.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1590-1590
Author(s):  
Laura Chu ◽  
Marianne Ulcickas Yood ◽  
Mahmoud Loghman-Adham ◽  
Karen Wells ◽  
Deborah Casso ◽  
...  
Keyword(s):  
Renal Impairment ◽  
Cancer Diagnosis ◽  
Preventive Measures ◽  
Renal Toxicity ◽  
Kidney Injury ◽  
Tumor Type ◽  
Newly Diagnosed ◽  
Tumor Registry ◽  
Henry Ford

1590 Background: Renal impairment is a common comorbidity in cancer pts. It can delay excretion and alter metabolism of anticancer drugs leading to further renal toxicity. The objective of this study was to determine the proportion of pts with renal impairment, defined as the presence of proteinuria (PR), acute kidney injury (AKI), or chronic kidney disease (CKD), after chemotherapy (chemo) initiation. Methods: LC, CRC, and BC pts newly diagnosed between 2000 and 2007 (regardless of prior renal status) were identified using the HFHS tumor registry, with follow-up through Mar 2009. AKI was defined based on RIFLE (severity categories only) using lab data within 1 to 7 days after chemo initiation. CKD was defined based on NKF-KDOQI criteria and lab data up to 1 year after chemo initiation. Proteinuria was defined as protein/creatinine >30 mg/g within 3 months after chemo initiation. Descriptive statistics include proportions stratified by renal impairment status (yes, no) at cancer diagnosis. Results: We identified 1,896 LC, 1,088 CRC, 1,611 BC chemo treated pts. Median age for all pts was 66 years. For LC and CRC, 56% and 51% were men, respectively. The proportion of pts with renal impairment after chemo by tumor type was the following: LC (AKI=23.4%; CKD=48.2%; PR=0.4%); CRC (AKI=20.3%; CKD=55.7%; PR=0.1%); BC (AKI=7.8%; CKD=63.9%; PR=0.6%). Pts with pre-existing renal impairment at cancer diagnosis were more likely to have impairment after chemo (Table). Conclusions: In LC, CRC, and BC pts, the proportion of pts with renal impairment after chemo initiation was high. Extent of renal impairment, especially AKI, appears to be associated with tumor type. Older age, as in this HFHS cohort, is associated with higher prevalence of CKD. Renal function should be closely monitored, particularly among pts with pre-existing renal impairment, and preventive measures implemented to minimize further toxicity after treatment.

scholarly journals Insurance Disparity in Cardiovascular Mortality among Non-Elderly Cancer Survivors

2021 ◽  
Author(s):  
Tiantian Shi ◽  
Changchuan Jiang ◽  
Cenjing Zhu ◽  
Fangcheng Wu ◽  
Irma Fotjhadi ◽  
...  
Keyword(s):  
General Population ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Private Insurance ◽  
Final Analysis ◽  
Vital Role ◽  
Cancer Site ◽  
Race And Gender ◽  
Cvd Mortality

Abstract Background:Insurance status plays a vital role in cancer diagnosis, treatments and survival. Cancer patients have higher cardiovascular disease (CVD) mortality than the general population. Methods: The Surveillance, Epidemiology and End Results (SEER) program 2007-2016 was used to estimate the CVD mortality among cancer patients aged 18 to 64 years at the time of diagnosis of an initial malignancy with the eight most prevalent cancers. Standardized mortality ratios (SMRs) were calculated for each insurance (Private vs Medicaid vs Uninsured) using coded cause of death from CVD with adjustment of age, race, and gender. The Fine-Grey Model was used to estimate adjusted Hazard Ratios (HR) of each insurance in CVD mortality. Results: A total of 768,055 patients were included in the final analysis. CVD death in patients with Medicaid insurance remained higher than in those with private insurance (HR=1.71; 95%CI, 1.61-1.81; p<0.001). Older age, male gender, and black race were all associated with increased CVD mortality in the multivariable model. Compared to the general population, patients with Medicaid had the highest SMRs of CVD mortality, regardless of year of cancer diagnosis, follow-up time, cancer site, and race. Private insured patients had similar CVD mortality to the general population after 2 years out from their cancer diagnosis. Conclusion: Cancer patients with private insurance have significantly lower CVD mortality than those with no insurance or Medicaid. The insurance disparity remained significant regardless of type of CVD, cancer site, year of diagnosis and follow-up time.

scholarly journals Insurance disparity in cardiovascular mortality among non-elderly cancer survivors

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Tiantian Shi ◽  
Changchuan Jiang ◽  
Cenjing Zhu ◽  
Fangcheng Wu ◽  
Irma Fotjhadi ◽  
...  
Keyword(s):  
General Population ◽  
Cancer Patients ◽  
Cancer Diagnosis ◽  
Final Analysis ◽  
Vital Role ◽  
Cancer Site ◽  
Race And Gender ◽  
And Gender ◽  
Cvd Mortality

Abstract Background Insurance status plays a vital role in cancer diagnosis, treatments and survival. Cancer patients have higher cardiovascular disease (CVD) mortality than the general population. Methods The Surveillance, Epidemiology and End Results (SEER) program 2007–2016 was used to estimate the CVD mortality among cancer patients aged 18 to 64 years at the time of diagnosis of an initial malignancy with the eight most prevalent cancers. Standardized mortality ratios (SMRs) were calculated for each insurance (Non-Medicaid vs Medicaid vs Uninsured) using coded cause of death from CVD with adjustment of age, race, and gender. The Fine-Grey Model was used to estimate adjusted Hazard Ratios (HR) of each insurance in CVD mortality. Results A total of 768,055 patients were included in the final analysis. CVD death in patients with Medicaid insurance remained higher than in those with Non-Medicaid insurance (HR = 1.71; 95%CI, 1.61–1.81; p < 0.001). Older age, male gender, and black race were all associated with increased CVD mortality in the multivariable model. Compared to the general population, patients with Medicaid had the highest SMRs of CVD mortality, regardless of year of cancer diagnosis, follow-up time, cancer site, and race. Non-Medicaid insured patients had similar CVD mortality to the general population after 2 years out from their cancer diagnosis. Conclusion Cancer patients with Non-Medicaid insurance have significantly lower CVD mortality than those with no insurance or Medicaid. The insurance disparity remained significant regardless of type of CVD, cancer site, year of diagnosis and follow-up time.

scholarly journals A ten year follow-up of key gas exchange exercise parameters in a general population – Results of the Study of Health in Pomerania

2020 ◽  
pp. 00350-2020
Author(s):  
Beate Stubbe ◽  
Till Ittermann ◽  
Sabine Kaczmarek ◽  
Anne Obst ◽  
Martin Bahls ◽  
...  
Keyword(s):  
Gas Exchange ◽  
General Population ◽  
Oxygen Uptake ◽  
Cardiopulmonary Exercise Testing ◽  
Observation Time ◽  
Healthy Individuals ◽  
Cardiorespiratory System ◽  
Cardiopulmonary Exercise ◽  
Age Range

BackgroundCardiopulmonary exercise testing (CPET) is a frequently used method for the evaluation of the cardiorespiratory system. The prognostic relevance of the measured parameters is commonly known. Longitudinal data on cardiorespiratory fitness in a large sample of well characterised healthy volunteers are rare in literature.MethodsCPET data of 615 healthy individuals who voluntarily took part in the Study of Health in Pomerania (SHIP) at three times were analysed. The median observation time was 10.5 years. The age range was 25 to 85 years.ResultsOver the observed timeframe and with rising age a decline in maximum power, oxygen uptake and oxygen uptake at the anaerobic threshold was detectable. This decline was aggravated with rising age. For the VÉ/VCO2 slope an increase in individuals older than 50 years was measured only.ConclusionThe present study affirms the decrease in aerobic capacity with increasing age in a selected, well characterised, healthy study sample, that seems to be less pronounced in women.

Sign in / Sign up

Export Citation Format

Share Document